Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms without original human experimental data or systematic search methodology
PubMed 35521962 · doi:10.1177/15353702221087962
What was done
This paper provides a narrative review discussing the molecular and systemic mechanisms underlying cancer-associated cachexia. It synthesizes existing concepts surrounding the spatio-temporal progression of cachexia, tumor-host metabolic competition, inflammatory signaling, central nervous system interactions, and emerging diagnostic and therapeutic approaches.
What was found
The abstract reports no original quantitative data or specific numerical endpoints. It describes qualitative pathophysiological pathways including elevated proteasome-mediated proteolysis, accelerated lipolysis, suppressed protein synthesis and lipogenesis, increased resting energy expenditure, and systemic neuroendocrine and inflammatory dysregulation affecting skeletal muscle, adipose tissue, and cardiac muscle.
Why it matters
Understanding the multi-organ metabolic crosstalk between tumor anabolism and host tissue catabolism helps clarify why cancer cachexia severely reduces tolerance to anti-neoplastic therapies and increases mortality, guiding future multimodal intervention strategies.
Limits
The abstract describes a narrative review rather than a systematic review or primary clinical trial. No sample size, quantitative effect estimates, meta-analytic statistics, or original experimental data are reported.
Cited by
- supports Cancer cachexia involves the mobilization of skeletal muscle proteins for gluconeogenesis and direct tumor utilization of glutamine.